GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
Clinical trial NCT03765983 · TERMINATED
Trial details
- NCT number
- NCT03765983
- Sponsor
- Dana-Farber Cancer Institute
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-02-25
- Primary completion
- 2024-04-29
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.